Saturday, November 14, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 19, 2026

5 Soft Drinks Stocks Set to Gain as Innovation Offsets Cost Pressures

View original at finance.yahoo.com
5 Soft Drinks Stocks Set to Gain as Innovation Offsets Cost Pressures The Zacks Beverages – Soft Drinks industry is gaining momentum as health-focused innovation and digital transformation reshape the landscape…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Companies leveraging AI-driven insights, e-commerce expansion and smart supply chains are strengthening consumer engagement, improving efficiency and positioning themselves for sustainable, long-term competitive advantage

    80% confidence
  • Coca-Cola has been witnessing a splurge in e-commerce, with the growth rate of the channel doubling in many countries

    80% confidence
  • Vita Coco looks well-poised for growth, driven by its ability to drive the brand volume increase via strong retail execution and creative marketing programs

    80% confidence
  • Rising demand for natural, low-sugar and functional beverages, along with expansion into adjacent categories like RTD alcoholic drinks, is fueling growth

    80% confidence
  • Monster Beverage has been experiencing continued strength in its energy drinks category, which is driving its performance

    80% confidence
  • PepsiCo expects strong growth and market share gains from the liquid refreshment beverage category, with share gains in the carbonated soft drinks, RTD Tea and water categories

    80% confidence
  • Volatility in sugar, packaging and freight expenses is prompting companies to recalibrate pricing actions and reconfigure supply chains

    80% confidence
  • The Soft Drinks industry is contending with mounting pressures as elevated input costs and tariff uncertainty squeeze margins and complicate production planning

    80% confidence
  • Keurig Dr Pepper is poised to gain from continued momentum in the Refreshment Beverages segment and solid market share growth

    80% confidence
  • Vita Coco's focus on growing the coconut water category resulted in its overall sales growth, witnessing a 15% CAGR for the last four years

    80% confidence
  • The top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1

    80% confidence
  • The Zacks Beverages - Soft Drinks industry is gaining momentum as health-focused innovation and digital transformation reshape the landscape

    80% confidence
  • Coca-Cola is poised to gain from strategic transformation and ongoing worldwide recovery

    80% confidence
  • Monster Beverage management is optimistic about the strength in the global energy drinks category

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,580 source documents archived
Query this data → isubstrate.com
5 Soft Drinks Stocks Set to Gain as Innovation Offsets Cost Pressures — Source | Via News | finance.via.news